A Phase 4 interventional study of Meropenem and Piperacillin/Tazobactam in Sepsis and Septic Shock, sponsored by Scandinavian Critical Care Trials Group. Recruiting at 2 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-03.
Sponsored by Scandinavian Critical Care Trials Group · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Shock, Septic with a site in Denmark — 3 open to participants now, 4 under way, 1 of them phase 3. Shock, Septic · Denmark.
Among the 27 studies in Shock, Septic with a site in Denmark, this one has the largest planned enrollment of the 18 interventional ones that give a count, is the only one that started in 2025, is one of 5 in phase 4, and was the 27th registered.
1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.
Browse Shock, Septic studies →3 of the 27 studies in Shock, Septic with a site in Denmark are open now. Recruiting first, the newest first:
Odense University Hospital · Sites in Denmark, Sweden
Ages 18+
Copenhagen University Hospital, Hvidovre · Sites in Denmark
Ages 18+
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 8 · Phase 3 6 · Phase 4 5
First in 2004; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 5,800 is above the median of 78 across 639 interventional studies indexed under Shock, Septic.
Median enrollment 300 across the 18 interventional studies, 50 across the 9 observational. Of the 18 that completed or were terminated, 5 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 27 have an industry lead sponsor. The 10 most frequent:
Scandinavian Critical Care Trials Group is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Scandinavian Critical Care Trials Group has 2 studies filed under Shock, Septic — fewer than ten, so there is no comparison to draw.
1 of the studies in Shock, Septic with a site in Denmark that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05931601Phase 3Odense University HospitalEarly Initiated Vasopressor Therapy in the Emergency Department | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 27 studies in Shock, Septic with a site in Denmark, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The EMPRESS trial aims to test the two most commonly used antibiotics (meropenem and piperacillin/tazobactam) among intensive care patients with sepsis (blood poisoning), as the safety of these two drugs is unclear in this group of patients.
Background Piperacillin/tazobactam and meropenem are commonly used as empirical agents for patients with sepsis or septic shock. In a recent systematic review comparing empirical and/or definitive treatment with piperacillin/tazobactam versus meropenem for patients with severe bacterial infections, including sepsis and septic shock, it was shown that piperacillin/tazobactam may be associated with less favourable outcomes based on low or very low certainty of evidence. At present, it is unclear if piperacillin/tazobactam and meropenem are equally effective and safe for adults with sepsis.
Objectives To assess the effects of empirical meropenem vs. piperacillin/tazobactam on mortality and other patient-important outcomes in critically ill adults with sepsis.
Design Investigator-initiated, international, parallel-group, randomised, open-label, adaptive clinical trial with an integrated feasibility phase. The EMPRESS trial will employ adaptive stopping rules to increase the chance that the trial will be conclusive and response-adaptive randomisation to increase each participant's chance of being randomised to the superior intervention arm.
Inclusion and exclusion criteria We will screen all adult patients who are critically ill with sepsis and who have indication for empirical treatment with meropenem or piperacillin/tazobactam. We will exclude patients with preceding intravenous treatment with meropenem or piperacillin/tazobactam for 24 hours or more; known pregnancy; known hypersensitivity or allergy to beta-lactam antibiotics; suspected or documented central nervous system infection; known infection or colonialisation with microorganism with acquired resistance to meropenem or piperacillin/tazobactam; current use of valproate; co-enrolment in other interventional trial where protocols collide; previous randomisation in EMPRESS; informed consent following inclusion expected to be unobtainable; and patients who are under coercive measures.
Experimental intervention IV meropenem 1 g three times daily for up to 30 days.
Control intervention IV piperacillin/tazobactam 4/0.5 g four times daily for up to 30 days.
Outcomes The primary outcome is all-cause mortality at 30 days after randomisation. The secondary outcomes are the occurrence at least one serious adverse reaction (i.e., anaphylactic reaction to IV piperacillin/tazobactam or meropenem, invasive fungal infection, pseudomembranous colitis, or toxic epidermal necrolysis) within 30 days of randomisation; the occurrence of new isolation precautions due to resistant bacteria within 30 days of randomisation; days alive without life support (i.e., invasive mechanical ventilation, circulatory support, or renal replacement therapy) from randomisation to day 30 and 90; days alive and out of hospital from randomisation to day 30 and 90; all-cause mortality at day 90 and 180; and health-related quality of life at day 180 using EQ-5D-5L index values and EQ VAS. The feasibility outcomes are time to completion of feasibility phase (i.e., 200 participants randomised), recruitment proportion, proportion of participants without consent to the use of data, protocol adherence, and retention proportion.
Statistics and stopping rules The trial will be analysed using Bayesian statistical methods with the primary analyses conducted in the intention-to-treat population. Outcomes will be analysed using logistic and linear regression models adjusted for relevant baseline characteristics and neutral and weakly informative to somewhat sceptical priors. Results will be presented as adjusted sample average treatment effects using both absolute (risk and mean differences) and relative (risk ratios and ratios of means) differences with 95% credible intervals and probabilities of benefit/harm. Adaptive analyses will start after follow-up and data collection concludes for 400 participants and every subsequent 300 participants up to a maximum of 14,000 participants. Adaptations will be based on data for the primary outcome. EMPRESS will use constant, symmetrical stopping rules for inferiority/superiority calibrated to keep the type 1 error rate at 5%. Further, the trial will be stopped for practical equivalence if there is 90% probability that the absolute risk difference between arms is less than 2.5%-points. Restricted response-adaptive randomisation will be used to ensure minimum allocation probabilities of 40% to both groups.
Missing data will be imputed, and relevant secondary analyses, sensitivity analyses, and analyses of heterogeneity in treatment effects according to pre-defined baseline characteristics will be undertaken once the trial has been stopped.
Trial design performance metrics Performance characteristics were evaluated assuming a 25% event probability for the primary outcome in the piperacillin/tazobactam arm and scenarios with no, small, and large differences corresponding to event probabilities of 25%, 22.5%, and 20% in the meropenem arm, respectively. The expected (mean) sample sizes under these scenarios are 5189, 5859, and 2570, respectively. The probabilities of conclusiveness (i.e., superiority or equivalence) are 99% in all scenarios, and the probabilities of superiority (power) are 72% and \& 99% in the small and large difference scenarios, respectively.
Estimated timeline
1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.
This study's planned enrollment of 5,800 is above the median of 78 across 639 interventional studies indexed under Shock, Septic.
Browse Shock, Septic studies →Scandinavian Critical Care Trials Group is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Compared within Shock, Septic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Sepsis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Critical illness defined as use of at least one of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in the experimental intervention arm will receive 1 g of IV meropenem three times daily administered according to usual clinical practice (i.e., intermittent-, prolonged-, or continuous infusion) until discharge from the participating site, death, or termination of empirical antibiotic therapy (including initiation of definitive treatment).
Drug: Meropenem
Participants in the control arm will receive 4/0.5 g of intravenous piperacillin/tazobactam four times daily administered according to usual clinical practice (i.e., intermittent-, prolonged-, or continuous infusion) until discharge from the participating site, death, or termination of empirical antibiotic therapy (including initiation of definitive treatment).
Drug: Piperacillin/Tazobactam
For meropenem, the standard dose is 1 g administered 3 times daily as a 30-minute intravenous (IV) infusion, and the high dose is 2 g administered 3 times daily by extended 3-hour infusion
Standard dose of piperacillin/tazobactam 4/0.5 g administered 4 times daily as a 30-minute intravenous (IV) infusion or 3 times daily by extended 4-hour infusions and the recommended high dose is 4/0.5 g administered 4 times daily by extended 3-hour infusion
All-cause mortality
Number of participant deaths from all causes at day 30 after randomisation.
Time frame: Baseline to 30 days after enrollment
Serious Adverse Reaction (SAR)
Number of participants with one or more serious adverse reactions (SARs, defined as anaphylactic shock to IV piperacillin/tazobactam or meropenem, invasive fungal infection, pseudomembranous colitis, or toxic epidermal necrolysis) within 30 days of randomisation.
Time frame: Baseline to 30 days after enrollment
Bacterial resistance
Number of participants with new isolation precautions due to one or more resistant bacteria within 30 days of randomisation.
Time frame: Baseline to 30 days after enrollment
Days alive without life support
Days alive without life support (i.e., invasive mechanical ventilation, circulatory support, or renal replacement therapy \[including days in between intermittent renal replacement therapy\]) from randomisation to day 30 and 90.
Time frame: Baseline to day 30 and day 90 after enrollment
Days alive and out of hospital
Days alive and out of hospital from randomisation to day 30 and 90.
Time frame: Day 30 and day 90 after enrollment
All-cause mortality
Number of participant deaths from any cause at day 90 and 180.
Time frame: Day 90 and day 180 after enrollment
Health-related Quality of Life (HRQoL)
HRQoL at day 180 using the 5-level EQ-5D version (EQ-5D-5L) index values (ranging from 0 to 100, where 0 represents the worst health you can imagine and 100 represents the best health you can imagine).
Time frame: Day 180 after enrollment
Plan to share: Yes — An anonymised version of the final dataset (without personal, identifiable information, with timestamps replaced by relative time differences with respect to the time of randomisation, and other measures as deemed relevant) may be shared with other researchers following a reasonable request (i.e., a research proposal outlining the objectives, methodologies, and plans for data usage) and subsequent approval by the EMPRESS Management Committee. Any sharing of data that is not considered anonymised will be after the necessary approvals; alternatively, aggregation, scrambling, or synthetic datasets (101) (i.e., datasets with similar structure and attempts to preserve the overall relationships between variables as the original dataset) may be shared. Data will generally only be shared after a grace period of at least 9 months following initial publication of results based on the data. Approved researchers will sign appropriate agreements to ensure compliance.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Data sharing details ↗ · www.cric.nu
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Jun 2028, 36 months after the start.
Of 39 non-industry phase 4 interventional studies under Shock, Septic, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 38. This study's planned 36 months is above that.
Counting every sponsor, half of 40 studies reached it within 24 months; a quarter within 16 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Meropenem
Scandinavian Critical Care Trials Group